ES2124257T3 - Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores. - Google Patents

Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores.

Info

Publication number
ES2124257T3
ES2124257T3 ES92910345T ES92910345T ES2124257T3 ES 2124257 T3 ES2124257 T3 ES 2124257T3 ES 92910345 T ES92910345 T ES 92910345T ES 92910345 T ES92910345 T ES 92910345T ES 2124257 T3 ES2124257 T3 ES 2124257T3
Authority
ES
Spain
Prior art keywords
composition
equipment
tumor activity
tumors
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910345T
Other languages
English (en)
Other versions
ES2124257T4 (es
Inventor
Tetsuhiko Shirasaka
Masakazu Fukushima
Hideyuki Ohshimo
Yuji Shimamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2124257T3 publication Critical patent/ES2124257T3/es
Publication of ES2124257T4 publication Critical patent/ES2124257T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UNA COMPOSICION PARA POTENCIAR LA ACTIVIDAD ANTITUMORAL DEL TEGAFUR Y REDUCIR LOS SUS EFECTOS ADVERSOS, LA COMPOSICION COMPRENDE UN COMPUESTO REPRESENTADO POR LA FORMULA GENERAL (I) EN LA QUE X REPRESENTA HALOGENO O CIANO Y ACIDO OXONICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, ASI COMO UN METODO Y UN EQUIPO PARA EL USO DEL COMPUESTO, ASIMISMO SE PRESENTA UNA COMPOSICION PARA CURAR TUMORES QUE COMPRENDE TEGAFUR, UN COMPUESTO REPRESENTADO POR LA FORMULA (I) Y UN ACIDO OXONICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; ASI COMO UN METODO Y UN EQUIPO PARA LOS MISMOS.
ES92910345T 1991-05-27 1992-05-22 Composición, método y equipo para la estimulación de la actividad antitumoral y para el tratamiento de tumores. Expired - Lifetime ES2124257T4 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12124791 1991-05-27
JP121247/91 1991-05-27
PCT/JP1992/000656 WO1992021345A1 (en) 1991-05-27 1992-05-22 Composition, method and kit for potentiating antitumor activity and for curing tumor

Publications (2)

Publication Number Publication Date
ES2124257T3 true ES2124257T3 (es) 1999-02-01
ES2124257T4 ES2124257T4 (es) 2012-03-23

Family

ID=14806544

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910345T Expired - Lifetime ES2124257T4 (es) 1991-05-27 1992-05-22 Composición, método y equipo para la estimulación de la actividad antitumoral y para el tratamiento de tumores.

Country Status (14)

Country Link
US (1) US5525603A (es)
EP (1) EP0543015B1 (es)
JP (1) JP2614164B2 (es)
KR (1) KR0148589B1 (es)
AT (1) ATE173165T1 (es)
AU (1) AU654555B2 (es)
CA (1) CA2087540C (es)
DE (2) DE122011100040I2 (es)
DK (1) DK0543015T3 (es)
ES (1) ES2124257T4 (es)
HU (1) HU211987A9 (es)
LU (1) LU91852I2 (es)
TW (1) TW209833B (es)
WO (1) WO1992021345A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
JPH11116564A (ja) * 1997-10-09 1999-04-27 Otsuka Chem Co Ltd クロモン誘導体
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
WO2000021956A1 (en) * 1998-10-12 2000-04-20 Leonidov Nikolai B New crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl)-uracyl, and complex compounds based on this modification and having an antitumoral activity
JP2002255828A (ja) * 2001-02-28 2002-09-11 Ajinomoto Co Inc 抗腫瘍剤
AU2003235761A1 (en) 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
US9611227B2 (en) * 2003-03-14 2017-04-04 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator and antitumor agent
ATE540679T1 (de) * 2004-04-29 2012-01-15 Taiho Pharmaceutical Co Ltd Verfahren zur verringerung der gastrointestinalen toxizität durch verabreichung von tegafur
KR100844477B1 (ko) 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
JP4956423B2 (ja) * 2005-04-01 2012-06-20 大鵬薬品工業株式会社 放射線治療増強剤
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
CN101921227B (zh) * 2007-04-03 2012-09-05 南京工业大学 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
WO2010104035A1 (ja) 2009-03-12 2010-09-16 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
KR101579638B1 (ko) 2009-03-31 2015-12-22 데루타-후라이 화마 가부시키가이샤 티미딜산 합성효소에 대한 ＲＮＡｉ 분자 및 그의 용도
TW201043237A (en) 2009-04-22 2010-12-16 Taiho Pharmaceutical Co Ltd Method for predicting a therapeutic effect of the chemotherapy for renal cell cancer
EP2431032A4 (en) 2009-05-12 2012-11-07 Taiho Pharmaceutical Co Ltd ANTICROBIAL AGENTS WITH A TEGAFUR GIMERACIL OTERACIL CALIUM COMBINATION AND OXALIPLATIN
ES2619937T3 (es) 2009-10-27 2017-06-27 Delta-Fly Pharma, Inc. Nuevo derivado de 5-fluorouracilo
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
WO2012105486A1 (ja) 2011-01-31 2012-08-09 Shirasaka Tetsuhiko １日1回隔日投与を特徴とするテガフール含有組成物
EP2711704B1 (en) 2011-05-16 2017-06-28 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
WO2012161240A1 (ja) 2011-05-25 2012-11-29 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠
CN103159673B (zh) * 2011-12-12 2015-02-04 山东新时代药业有限公司 一种制备吉美嘧啶的精制方法
JPWO2013137433A1 (ja) 2012-03-16 2015-08-03 大鵬薬品工業株式会社 ３剤を組み合わせた新規な抗腫瘍剤
WO2013180274A1 (ja) * 2012-06-01 2013-12-05 大鵬薬品工業株式会社 胃癌患者に対する化学療法の選択方法
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
JPS562913A (en) * 1979-06-21 1981-01-13 Ono Pharmaceut Co Ltd Antitumor agent
JPS5646867A (en) * 1979-09-25 1981-04-28 Ono Pharmaceut Co Ltd Pyridone derivative, its preparation and antineoplasmic agent
DE3585869D1 (de) * 1984-10-30 1992-05-21 Otsuka Pharma Co Ltd Zusammensetzung zur steigerung der antikrebsaktivitaet einer antikrebsverbindung.
JPS62155215A (ja) * 1984-11-30 1987-07-10 Otsuka Pharmaceut Co Ltd 抗腫瘍活性増強剤
DE69003670T2 (de) * 1989-01-05 1994-01-27 Otsuka Pharma Co Ltd Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
JPH0578249A (ja) * 1991-09-20 1993-03-30 Taiho Yakuhin Kogyo Kk ５−フルオロウラシル類により起こる嘔気・嘔吐の防止及び治療剤

Also Published As

Publication number Publication date
JP2614164B2 (ja) 1997-05-28
ATE173165T1 (de) 1998-11-15
ES2124257T4 (es) 2012-03-23
WO1992021345A1 (en) 1992-12-10
EP0543015A4 (en) 1994-06-01
DE122011100040I1 (de) 2011-11-24
AU654555B2 (en) 1994-11-10
AU1791292A (en) 1993-01-08
TW209833B (es) 1993-07-21
HU211987A9 (en) 1996-01-29
KR0148589B1 (ko) 1998-11-02
LU91852I2 (fr) 2011-10-03
DE122011100040I2 (de) 2012-08-09
DE69227571T2 (de) 1999-04-29
DE69227571D1 (de) 1998-12-17
US5525603A (en) 1996-06-11
EP0543015A1 (en) 1993-05-26
EP0543015B1 (en) 1998-11-11
CA2087540C (en) 1999-01-19
DK0543015T3 (da) 1999-07-26
CA2087540A1 (en) 1992-11-28

Similar Documents

Publication Publication Date Title
ES2137932T3 (es) Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2093694T3 (es) Nuevos derivados de dihidro-isoquinoleina.
ES8500276A1 (es) Procedimiento para preparar n2-acil-9-(1,3-dihidroxi-2-propoximetil)-guaninas y sus sales famaceuticamente aceptables.
DK339184D0 (da) Imidazoliumforbindelser, mellemprodukter hertil og fremgangsmaade til deres anvendelse
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
FI865233A0 (fi) Pyrazolinderivat, deras framstaellning och anvaendning som medel med insekticid och akaricid verkan.
ES8704170A1 (es) Un procedimiento para preparar derivados de guanina
ES8302025A1 (es) Procedimiento para la preparacion de 10-alquinil esteroides
ES8504183A1 (es) Un nuevo procedimiento para la preparacion de nuevos cromanos y cromenos.
ES2009723A4 (es) Derivados de acidos biliares, procedimientos para la preparacion de los mismos y composiciones farmaceuticas conteniendolos.
DE69015736D1 (de) 7-Keto- und 7-Hydroxy-androsta-3,5-dien-3-carbonsäure Derivate.
ES2055037T3 (es) Derivados de 4-amino-3-acil-quinolina y su uso como inhibidores de la secrecion de acido gastrico.
ES2045044T3 (es) Derivados de sulfonamidolfenilo y agentes terapeuticos y preventivos de la arritmia que contienen los mismos.
ES8402297A1 (es) Un procedimiento de preparacion de derivados de imidazo-(1,2-)piridina.
FI895447A0 (fi) Substituerade adeninderivat anvaendbara som terapeutiska substanser.
GR78806B (es)
ATE30583T1 (de) Vitamin-d3-derivate.
ES2062758T3 (es) Nuevos analogos de vitamina d.
ES2091249T3 (es) Analogos de iludina utilizables como agentes antitumorales.
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
NO932722L (no) Salter av et 4-amino-3acyl-kinolinderivat og deres anvendelse som inhibatorer for gastrisk syresekresjon
ES8502435A1 (es) Un metodo para preparar 2(1h)-piridinonas
MX9300008A (es) Nucleosidos terapeuticos.
ES8504182A1 (es) Procedimiento para preparar nuevos derivados de piperidina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 543015

Country of ref document: ES